MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman

San Francisco, California--(Newsfile Corp. - November 13, 2025) - A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa or "HS").

On this announcement, MoonLake investors saw the price of their shares crater $55.75, or about 90%, on September 29, 2025.

The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to investigate claims that, prior to September 28, 2025, MoonLake misled investors about SLK's trial design and efficacy data.

The firm urges investors in MoonLake who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Class Period: Mar. 10, 2024 - Sep. 29, 2025
Lead Plaintiff Deadline: Dec. 15, 2025
Visit: www.hbsslaw.com/investor-fraud/mltx
Contact the Firm Now: [e-mail]
844-916-0895

MoonLake Immunotherapeutics (MLTX) Securities Class Action:

The litigation is focused on the propriety of MoonLake's statements about the trial design and data for SLK. The clinical stage biotechnology company is focused on skin inflammatory diseases driven by a cytokines known as IL-17A and IL-17F.

Central to SLK's commercial prospects was its ability to demonstrate efficacy in HS comparable or superior to a competitor's FDA-approved product ("BIMZELX"), which is used for the same HS indication and targets the same cytokines.

One difference between SLK and BIMZELX is that SLK's Nanobody structure is significantly smaller than BIMZELX's monoclonal antibody format.

Throughout the Class Period, MoonLake repeatedly touted SLK's structural advantages as translating into superior efficacy. The company has said that SLK could achieve benefits "a monoclonal antibody cannot do," that "the molecular advantages of our Nanobody translate into higher clinical responses for patients," and that Nanobodies "offer a more convenient and effective treatment."